Building in oncology, Jazz obtains targeted glioma therapy under FDA review

Deepening commitment to oncology, Jazz elects to maintain license for dual HER2 bispecific; Phase IIb results this week could suffice for targeted approval

Plus AZ’s AKT inhibitor hits co-primary endpoints in breast cancer trial, and updates from Time BioVentures, Seres, Jazz and GSK

Jazz pays $50M up front for rights to HER2-targeting bispecific, would owe more than 6x more to retain them after first pivotal readout

Jazz pays $15M up front to in-license rights to Werewolf’s conditionally activated oncology therapeutic

With the acquisition of cannabinoid therapeutics company GW in Jazz’s largest deal ever, the company added a product and pipeline that complements its historical strength in neuroscience rather

PharmaMar will likely need to conduct a new study of Zepzelca to gain its full approval after the drug failed to show a survival benefit in a potentially confirmatory Phase III trial to treat small